Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention
Maher Rabah, DO*,
Denise Mason, BSN*,
David W. M. Muller, MD, FACC ,
Randal Hundley, MD, FACC ,
Aaron D. Kugelmass, MD, FACC||,
Bonnie Weiner, MD, FACC¶,
Louis Cannon, MD, FACC¶,
William W. ONeill, MD, FACC* and
Robert D. Safian, MD, FACC*
* Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan, USA
Department of Cardiology, St. Vincents Hospital, Sydney, Australia
Department of Cardiology, Baptist Medical Center, Little Rock, Arkansas, USA
Department of Cardiology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
|| Department of Cardiology, University of Massachusetts Medical Center, Worcester, Massachusetts, USA
¶ Department of Cardiology, Saginaw, Michigan, USA

View larger version (20K):
[in a new window]
|
Figure 1 The combined incidence of bleeding and vascular events after successful percutaneous coronary intervention. Solid box = Group 1; striped box = Group 2; open box = Group 3. *p = 0.01; **p < 0.01; ***p = 0.07.
|
|

View larger version (10K):
[in a new window]
|
Figure 2 Baseline (PRE) and postprocedural (NADIR) hemoglobin concentrations in patients undergoing percutaneous coronary intervention.
|
|

View larger version (27K):
[in a new window]
|
Figure 4 Total adjusted Medicare cost after successful percutaneous coronary catheterization. p < 0.0001. Solid box = Group 1; striped box = Group 2; open box = Group 3.
|
|
|